Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: Data from 3 large randomized clinical trials Meeting Abstract

sustainable development goals

publication date

  • September 1, 2018

webpage

published in

start page

  • AB166

end page

  • AB166

volume

  • 79

issue

  • 3